Recent Advancements in aptamer-bioconjugates: Sharpening Stones for breast and prostate cancers targeting

Saeid Maghsoudi, Bahareh Taghavi Shahraki, Navid Rabiee, Ronak Afshari, Yousef Fatahi, Rassoul Dinarvand, Sepideh Ahmadi, Mojtaba Bagherzadeh, Mohammad Rabiee, Lobat Tayebi, Mohammadreza Tahriri*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

27 Citations (Scopus)


Breast and prostate cancers are common types of cancers with various strategies, such as chemotherapy and radiotherapy, for their therapy. Since these methods have undesired side effects and poor target affinity, neoteric strategies—known as aptamer-based smart drug delivery systems (SDDSs)—have been developed in recent years to overcome the obstacles of current treatment, and investigated for a clinical trial. The high affinity and versatility of aptamers for binding to the corresponding targets make them highly noticeable agents in the drug delivery domains. In addition to their exceptional benefits, aptamers are able to overcome tumor resistance because of their high selectivity and low toxicity. Furthermore, aptamers can conjugate with various drugs, nanoparticles and antibodies and effectively deliver them to the specific breast and prostate cells. This review highlights the current researches in aptamer-conjugate developments for targeting breast and prostate cancers, with the special focus on the nanoparticle-aptamer bioconjugates, systematic evolution of ligands by exponential enrichment (SELEX) system and SDDS, especially cutting-edge articles from 2008 to present. Finally, the future prospects and challenges are described.

Original languageEnglish
Article number101146
Pages (from-to)1-12
Number of pages12
JournalJournal of Drug Delivery Science and Technology
Publication statusPublished - Oct 2019
Externally publishedYes


  • Aptamer
  • Breast and prostate cancers
  • Nanoparticle
  • Smart drug delivery system
  • Tumor resistance


Dive into the research topics of 'Recent Advancements in aptamer-bioconjugates: Sharpening Stones for breast and prostate cancers targeting'. Together they form a unique fingerprint.
  • Novel nanocarriers for drug delivery applications

    Rabiee, N., Ghadiri, A. M., Safarkhani, M., Fatahi, Y., Kiani, M., Ahmadi, S., Mozafari, M., Saeb, M. R., Makvandi, P., Hamblin, M. R., Varma, R. S., Rabiee, M., Mostafavi, E., Zarrintaj, P., Hamed Mashhadzadeh, A., Tahriri, M., Tayebi, L. & Shokouhimehr, M.

    10/09/18 → …

    Project: Research

Cite this